Ado-trastuzumab emtansine (trastuzumab emtansine) is an antibody-drug conjugate marketed as Kadcyla for HER2-positive breast cancer settings. It combines trastuzumab with the cytotoxic agent DM1 to deliver targeted anti-tumor activity after HER2 binding and internalization. FDA marketing approval was first granted in 2013.
Trastuzumab deruxtecan is moving into earlier treatment lines for HER2-positive metastatic breast cancer, demonstrating superior efficacy over standard regimens and prompting reconsideration of long-standing treatment sequences.
Exploratory analysis from a phase 1/2 trial shows CD47 expression levels predict response to evorpacept plus zanidatamab in heavily pretreated HER2-positive metastatic breast cancer patients, supporting biomarker-driven patient selection.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04296942 |
BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) |
TERMINATED | PHASE1 |
| NCT03364348 |
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer |
COMPLETED | PHASE1 |
| NCT02675829 |
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT02318901 |
Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer |
TERMINATED | PHASE1/PHASE2 |
| NCT02226276 |
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer |
ACTIVE_NOT_RECRUITING | NA |
| NCT02038010 |
BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx |
COMPLETED | PHASE1 |
| NCT01494662 |
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases |
COMPLETED | PHASE2 |
| NCT00833963 |
A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine |
COMPLETED |
